Vyant Bio Inc (VYNT)

Sector:
HEALTH CARE
Industry:
HEALTH CARE SUPPLIES
SIC:
SERVICES-MEDICAL LABORATORIES
CEO:
Jay Roberts
Employees:
150
2370 STATE ROUTE 70 WEST, SUITE 310, CHERRY HILL, NJ, 08002
201.528.9200

Vyant Bio is a vital new force in drug discovery. We are ready to efficiently, and with greater predictive value, identify the most viable, safe and effective drug candidates. We can accomplish this by uniting the leading human-based microOrgan technology, unsurpassed data science and machine learning, world-class IND-enabling development strategies, and global regulatory focus—in one seamless, comprehensive and reliable resource. The company is headquartered in Cherry Hill, NJ.

Data derived from most recent annual or quarterly report
Market Cap 24.322 Million Shares Outstanding28.99 Million Avg 30-day Volume 217.942 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-1.2
Price to Revenue16.6218 Debt to Equity0.0141 EBITDA-14.515 Million
Price to Book Value1.8548 Operating Margin-627.6843 Enterprise Value25.363 Million
Current Ratio2.739 EPS Growth0.789 Quick Ratio2.279
1 Yr BETA 0.8002 52-week High/Low 4.11 / 0.6 Profit Margin-1708.9744
Operating Cash Flow Growth-84.8341 Altman Z-Score-2.3597 Free Cash Flow to Firm -12.675 Million
View SEC Filings from VYNT instead.

View recent insider trading info

Vyant Bio Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding VYNT (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding VYNT BETA

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2022-04-19 by HOROBIN JOANNA
  • 4: filed on 2022-04-19 by HANSEN PAUL R.
  • 4: filed on 2022-04-19 by FLETCHER R JOHN
  • 4: filed on 2022-04-19 by HARRIS GEOFFREY E.
  • 4: filed on 2022-04-19 by BOEHM MARCUS
  • 4: filed on 2022-04-13 by FLETCHER R JOHN
  • 4: filed on 2022-04-01 by HOROBIN JOANNA
  • 4: filed on 2022-04-01 by HANSEN PAUL R.
  • 4: filed on 2022-04-01 by MCLEOD HOWARD
  • 4: filed on 2022-04-01 by YEH YUNG-PING

    • Events (8k)

  • 8-K: filed on 2022-06-13:
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-05-26:
    Item 5.08: Shareholder Nominations Pursuant to Exchange Act Rule 14a-11
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-05-20:
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-05-16:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-05-16:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-04-11:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-03-01:
    Item 2.02: Results of Operations and Financial Condition
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-01-24:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 8.01: Other Events
  • 8-K: filed on 2021-10-26:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-08-16:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits

    • Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    FLETCHER R JOHN

    • Director
    		 114,963 2022-04-18 4

    HOROBIN JOANNA

    • Director
    		 55,617 2022-04-18 3

    HARRIS GEOFFREY E.

    • Director
    		 56,938 2022-04-18 3

    HANSEN PAUL R.

    • Director
    		 732,838 2022-04-18 4

    BOEHM MARCUS

    • Director
    		 185,270 2022-04-18 9

    MCLEOD HOWARD

    • Director
    		 43,927 2022-03-30 1

    YEH YUNG-PING

    • Director
    		 1,371,603 2022-03-30 3

    ROBERTS JOHN A CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    		 150,000 2022-03-15 3

    LAFRENCE ANDREW D.C. CHIEF FINANCIAL OFFICER

    • Officer
    		 110,000 2022-03-15 3

    FREMEAU ROBERT THOMAS JR. CHIEF SCIENTIFIC OFFICER

    • Officer
    		 75,000 2022-03-15 3

    BRANDT RALF PRESIDENT, DISCOVERY SERVICES

    • Officer
    		 100,000 2021-03-30 0

    MILES MICHAEL GLENN CHIEF FINANCIAL OFFICER

    • Officer
    		 0 2020-01-02 0

    PRENDERGAST FRANKLYN G

    • Director
    		 0 2019-07-23 0

    CHAGANTI RAJU S.K.

    • Director
    		 0 2019-07-23 0

    CANNON EDMUND

    • Director
    		 0 2019-07-23 0

    PAPPAJOHN JOHN

    • Director
    		 4,781,204 2019-01-31 0

    FINGER WILLIAM LANSING EVP PRECISION MEDICINE

    • Officer
    		 0 2019-01-04 0

    MCCARTNEY MICHAEL BRIAN CHIEF COMMERCIAL OFFICER

    • Officer
    		 0 2018-08-15 0

    SHAKNOVICH RITA CHIEF MEDICAL OFFICER

    • Officer
    		 0 2018-05-10 0

    WIDMANN THOMAS F

    • Director
    		 0 2017-11-21 0

    WELSH MICHAEL J.

    • Director
    		 12,540 2017-09-28 0

    GITELMAN IGOR CHIEF ACCOUNTING OFFICER

    • Officer
    		 15,000 2017-05-23 0

    SHARMA PANNA CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    		 0 2017-02-22 0

    SITAR EDWARD J CHIEF FINANCIAL OFFICER

    • Officer
    		 14,167 2016-11-16 0

    HEPBURN STEVEN

    • FORMER OFFICER
    		 No longer subject to file 2015-10-19 0

    EL NAGGAR JANE HOULDSWORTH VP OF RESEARCH AND DEVELOPMENT

    • Officer
    		 0 2014-12-11 0

    BROWNLIE KEITH L

    • Director
    		 5,000 2014-05-22 0

    ROTHMAN PAUL

    • Director
    		 5,000 2014-05-22 0

    PECORA ANDREW L

    • Director
    		 2,391 2013-11-18 0

    THOMPSON TOMMY G

    • Director
    		 2,500 2013-10-10 0

    CZEREPAK ELIZABETH CHIEF FINANCIAL OFFICER

    • Officer
    		 0 2013-04-04 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    VYANT BIO INC VYNT 2022-06-24 22:15:03 UTC -23.6716 25.2416 350000
    VYANT BIO INC VYNT 2022-06-24 21:45:03 UTC -23.6716 25.2416 350000
    VYANT BIO INC VYNT 2022-06-24 21:15:04 UTC -23.6716 25.2416 350000
    VYANT BIO INC VYNT 2022-06-24 20:45:03 UTC -23.4827 25.0527 350000
    VYANT BIO INC VYNT 2022-06-24 20:15:03 UTC -23.4827 25.0527 350000
    VYANT BIO INC VYNT 2022-06-24 19:45:03 UTC -23.4827 25.0527 350000
    VYANT BIO INC VYNT 2022-06-24 19:15:03 UTC -23.4827 25.0527 350000
    VYANT BIO INC VYNT 2022-06-24 18:45:03 UTC -23.5149 25.0849 350000
    VYANT BIO INC VYNT 2022-06-24 18:15:04 UTC -23.5149 25.0849 350000
    VYANT BIO INC VYNT 2022-06-24 17:45:03 UTC -23.5149 25.0849 350000
    VYANT BIO INC VYNT 2022-06-24 17:15:03 UTC -23.5149 25.0849 350000
    VYANT BIO INC VYNT 2022-06-24 16:45:03 UTC -22.2139 23.7839 350000
    VYANT BIO INC VYNT 2022-06-24 16:15:03 UTC -22.2139 23.7839 350000
    VYANT BIO INC VYNT 2022-06-24 15:45:03 UTC -22.2139 23.7839 300000
    VYANT BIO INC VYNT 2022-06-24 15:15:03 UTC -22.2139 23.7839 300000
    VYANT BIO INC VYNT 2022-06-24 14:45:03 UTC -24.1838 25.7538 300000
    VYANT BIO INC VYNT 2022-06-24 14:15:03 UTC -24.1838 25.7538 300000
    VYANT BIO INC VYNT 2022-06-24 13:45:03 UTC -24.1838 25.7538 300000
    VYANT BIO INC VYNT 2022-06-24 13:15:03 UTC -24.1838 25.7538 300000
    VYANT BIO INC VYNT 2022-06-24 12:45:03 UTC -24.1838 25.7538 300000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund VYNT -200.0 shares, $-286.0 2022-03-31 N-PORT

    Elevate your investments